Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies

Bibliography

• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-8; 2 p following 8
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52(20):1628-36
   PubMed Web of Science ®Google Scholar
• Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165(5):490-6
   PubMed Web of Science ®Google Scholar
• Duong M, Salvo F, Pariente A, et al. Usage patterns of “over the counter” versus prescription-strength non-steroidal anti-inflammatory drugs in France. Br J Clin Pharmacol 2013; In press
   Google Scholar
• Depont F, Fourrier A, Merliere Y, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007;16(8):891-900
   PubMed Web of Science ®Google Scholar
• Moore N, Salvo F, Duong M, et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf 2014;13(2):167-79
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(5):413-21
   PubMed Web of Science ®Google Scholar
• Giuliano F, Warner TD. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol 1999;126(8):1824-30
   PubMed Web of Science ®Google Scholar
• Kato M, Nishida S, Kitasato H, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001;53(12):1679-85
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296(2):558-66
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96(13):7563-8
   Google Scholar
• Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998;47(Suppl 2):S93-101
   PubMedGoogle Scholar
• Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351(17):1709-11
   PubMed Web of Science ®Google Scholar
• Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006;29(7):621-32
   PubMed Web of Science ®Google Scholar
• Tegeder I, Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol 2006;373(1):1-17
   PubMed Web of Science ®Google Scholar
• Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003;65(2):153-9
   PubMed Web of Science ®Google Scholar
• Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006;24(8):1457-69
   PubMed Web of Science ®Google Scholar
• Knights KM, Winner LK, Elliot DJ, et al. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 2009;68(3):402-12
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169(2):141-9
   PubMed Web of Science ®Google Scholar
• Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363(9423):1751-6
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Woodman RJ, Gilbert AL, et al. Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 2010;19(5):490-8
   PubMed Web of Science ®Google Scholar
• Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and Fever : a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig 2007;27(3):163-95
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011;20(12):1225-36
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and use of individual Non-steroidal anti-inflammatory drugs: meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013;22(6):559-70
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8(9):e1001098
   PubMed Web of Science ®Google Scholar
• Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011;89(6):855-66
   PubMed Web of Science ®Google Scholar
• ADAPT RG. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1(7):e33
   PubMedGoogle Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368(9549):1771-81
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005;118(11):1271-8
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89(4):425-30
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102
   PubMed Web of Science ®Google Scholar
• Andersohn F, Schade R, Suissa S, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006;37(7):1725-30
   PubMed Web of Science ®Google Scholar
• Roumie CL, Mitchel EF Jr, Kaltenbach L, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008;39(7):2037-45
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007;25(8):913-24
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3:17
   PubMed Web of Science ®Google Scholar
• Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113(16):1950-7
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165(9):978-84
   PubMed Web of Science ®Google Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2(3):155-63
   PubMed Web of Science ®Google Scholar
• Jick H, Kaye JA, Russmann S, et al. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006;26(10):1379-87
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Jick H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br J Clin Pharmacol 2007;64(5):662-7
   PubMed Web of Science ®Google Scholar
• Roumie CL, Choma NN, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009;18(11):1053-63
   PubMed Web of Science ®Google Scholar
• Cunnington M, Webb D, Qizilbash N, et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf 2008;17(6):601-8
   PubMed Web of Science ®Google Scholar
• Velentgas P, West W, Cannuscio CC, et al. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 2006;15(9):641-52
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289(21):2819-26
   PubMed Web of Science ®Google Scholar
• Soininen H, West C, Robbins J, et al. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23(1):8-21
   PubMed Web of Science ®Google Scholar
• Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347(26):2104-10
   PubMed Web of Science ®Google Scholar
• Koo BK, Kim YS, Park KW, et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 2007;370(9587):567-74
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355(9):885-95
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355(9):873-84
   PubMed Web of Science ®Google Scholar
• Feng GS, Ma JL, Wong BC, et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol 2008;14(28):4535-9
   PubMed Web of Science ®Google Scholar
• Reginster JY, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007;66(7):945-51
   PubMed Web of Science ®Google Scholar
• Scott DL, Berry H, Capell H, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology 2000;39(10):1095-101
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52(4):1205-15
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286(8):954-9
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-80
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib. N Engl J Med 2004;351(26):2767
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006;296(13):1619-32
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Gonzalez-Perez A, Bueno H, et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011;6(2):e16780
   PubMedGoogle Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. Expert Opin Drug Saf 2008;7(1):29-42
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123(20):2226-35
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3(4):395-405
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85(2):190-7
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113(25):2906-13
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide Study. PLoS One 2013;8(1):e54309
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162(10):1099-104
   PubMed Web of Science ®Google Scholar
• Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343(16):1139-47
   PubMed Web of Science ®Google Scholar
• Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350(14):1387-97
   PubMed Web of Science ®Google Scholar
• Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14(2):115-20
   PubMed Web of Science ®Google Scholar
• Moore N, Tubert-Bitter P, Fourrier A, et al. A simple method to estimate sample sizes for safety equivalence studies using inverse sampling. J Clin Epidemiol 2003;56(5):433-5
   PubMed Web of Science ®Google Scholar